Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oncology Institute (TOI) Income from Continuing Operations (2020 - 2025)

Oncology Institute's Income from Continuing Operations history spans 6 years, with the latest figure at 7508000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 43.04% year-over-year to 7508000.0; the TTM value through Dec 2025 reached 60606000.0, up 6.27%, while the annual FY2025 figure was 60606000.0, 6.27% up from the prior year.
  • Income from Continuing Operations reached 7508000.0 in Q4 2025 per TOI's latest filing, up from 16504000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 19286000.0 in Q1 2022 to a low of 29998000.0 in Q1 2023.
  • Average Income from Continuing Operations over 5 years is 10955600.0, with a median of 14330500.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 2036.35% in 2022, then plummeted 551.42% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 10156000.0 in 2021, then decreased by 8.38% to 11007000.0 in 2022, then plummeted by 70.38% to 18754000.0 in 2023, then grew by 29.71% to 13182000.0 in 2024, then soared by 43.04% to 7508000.0 in 2025.
  • Per Business Quant, the three most recent readings for TOI's Income from Continuing Operations are 7508000.0 (Q4 2025), 16504000.0 (Q3 2025), and 17009000.0 (Q2 2025).